Article

Steven Grossman, MD, PhD, Named Cancer Physician in Chief of USC Norris Comprehensive Cancer Center

Renowned oncologist and cancer researcher will begin inaugural position in September.

Steven Grossman, MD, PhD

USC Norris Comprehensive Cancer Center and Keck Medicine of USC have named renowned oncologist and cancer researcher Steven Grossman, MD, PhD, as the center’s cancer physician in chief.

In this inaugural position, Grossman will provide executive leadership of oncology services, partnering with academic and clinical leaders to advance new models of multidisciplinary care delivery. He will also serve as a professor of medicine at the Keck School of Medicine of USC.

“We are thrilled that Dr. Grossman will join us,” says Caryn Lerman, PhD, director of the USC Norris Comprehensive Cancer Center and associate dean for cancer programs at the Keck School. “His exceptional experience and track record as a clinical and scientific leader will enable us to accelerate our mission of delivering the most innovative, evidence-based care to our diverse patient population.”

Grossman, an internationally recognized expert in gastrointestinal cancers, is a past recipient of a Research Scholar award from the American Cancer Society, the Kimmel Scholar award from the Sidney Kimmel Foundation for cancer research and a Howard Temin Award in cancer research from the National Cancer Institute.

He previously served as the deputy director and Dianne Nunnally Hoppes Endowed Chair in Cancer Research at Virginia Commonwealth University Massey Cancer Center and as the chair of the division of hematology, oncology and palliative care.

“I am truly honored to join USC Norris in this newly created position,” Grossman says. “I am excited to expand USC Norris’ exceptional patient-focused clinical cancer services that provide multidisciplinary care and integrate cutting-edge clinical research at every level of the patient experience.”

Grossman received his undergraduate degree from Princeton University and his medical and doctoral degrees from the University of Chicago. He completed a residency in internal medicine at the Harvard Medical School-affiliated Brigham and Women’s Hospital, and completed a fellowship in medical oncology and postdoctoral research training at the Dana-Farber Cancer Institute.

Grossman begins his new role on September 15, 2020.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity